{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:11:28Z","timestamp":1790993488849,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-04151-9","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T06:23:27Z","timestamp":1743402207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A retrospective analysis of the efficacy and safety of oral tofacitinib in active vitiligo treatment"],"prefix":"10.1007","volume":"317","author":[{"given":"Wenting","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-e","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"4151_CR1","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","volume":"26","author":"ML Frisoli","year":"2020","unstructured":"Frisoli ML, Essien K, Harris JE, Vitiligo (2020) Mechanisms of pathogenesis and treatment. Annu Rev Immunol 38:621\u2013648. https:\/\/doi.org\/10.1146\/annurev-immunol-100919-023531","journal-title":"Annu Rev Immunol Apr"},{"issue":"3","key":"4151_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4103\/0378-6323.32708","volume":"73","author":"VN Sehgal","year":"2007","unstructured":"Sehgal VN, Srivastava G (2007) Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol 73(3):149\u2013156. https:\/\/doi.org\/10.4103\/0378-6323.32708","journal-title":"Indian J Dermatol Venereol Leprol May-Jun"},{"issue":"2","key":"4151_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1056\/NEJMcp0804388","volume":"8","author":"A Taieb","year":"2009","unstructured":"Taieb A, Picardo M (2009) Clinical practice. Vitiligo. N Engl J Med 360(2):160\u2013169. https:\/\/doi.org\/10.1056\/NEJMcp0804388","journal-title":"N Engl J Med Jan"},{"issue":"2","key":"4151_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1001\/jamadermatol.2013.927","volume":"149","author":"JI Silverberg","year":"2013","unstructured":"Silverberg JI, Silverberg NB (2013) Association between vitiligo extent and distribution and quality-of-life impairment. JAMA Dermatol 149(2):159\u2013164. https:\/\/doi.org\/10.1001\/jamadermatol.2013.927","journal-title":"JAMA Dermatol Feb"},{"issue":"5","key":"4151_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jaad.2015.07.039","volume":"73","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine K, Sheth V, Rodrigues M et al (2015) Vitiligo is not a cosmetic disease. J Am Acad Dermatol 73(5):883\u2013885. https:\/\/doi.org\/10.1016\/j.jaad.2015.07.039","journal-title":"J Am Acad Dermatol Nov"},{"issue":"2","key":"4151_CR6","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/bjd.13839","volume":"173","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine K, Grimes PE, Meurant JM et al (2015) Living with vitiligo: results from a National survey indicate differences between skin phototypes. Br J Dermatol 173(2):607\u2013609. https:\/\/doi.org\/10.1111\/bjd.13839","journal-title":"Br J Dermatol Aug"},{"issue":"4","key":"4151_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/bjd.16049","volume":"178","author":"O Osinubi","year":"2018","unstructured":"Osinubi O, Grainge MJ, Hong L et al (2018) The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol 178(4):863\u2013878. https:\/\/doi.org\/10.1111\/bjd.16049","journal-title":"Br J Dermatol Apr"},{"issue":"11","key":"4151_CR8","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1111\/jdv.19450","volume":"37","author":"J Seneschal","year":"2023","unstructured":"Seneschal J, Speeckaert R, Taieb A et al (2023) Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international vitiligo task Force-Part 2: specific treatment recommendations. J Eur Acad Dermatol Venereol 37(11):2185\u20132195. https:\/\/doi.org\/10.1111\/jdv.19450","journal-title":"J Eur Acad Dermatol Venereol Nov"},{"issue":"4","key":"4151_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/jamadermatol.2024.0021","volume":"1","author":"Y Renert-Yuval","year":"2024","unstructured":"Renert-Yuval Y, Ezzedine K, Grimes P et al (2024) Expert recommendations on use of topical therapeutics for vitiligo in pediatric, adolescent, and young adult patients. JAMA Dermatol 160(4):453\u2013461. https:\/\/doi.org\/10.1001\/jamadermatol.2024.0021","journal-title":"JAMA Dermatol Apr"},{"issue":"9","key":"4151_CR10","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/jid.2009.32","volume":"129","author":"JG van den Boorn","year":"2009","unstructured":"van den Boorn JG, Konijnenberg D, Dellemijn TA et al (2009) Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 129(9):2220\u20132232. https:\/\/doi.org\/10.1038\/jid.2009.32","journal-title":"J Invest Dermatol Sep"},{"issue":"7","key":"4151_CR11","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/jid.2011.463","volume":"132","author":"JE Harris","year":"2012","unstructured":"Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA (2012) A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin. J Invest Dermatol 132(7):1869\u20131876. https:\/\/doi.org\/10.1038\/jid.2011.463","journal-title":"J Invest Dermatol Jul"},{"issue":"1","key":"4151_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4049\/jimmunol.1900027","volume":"1","author":"RL Riding","year":"2019","unstructured":"Riding RL, Harris JE (2019) The role of memory CD8(+) T cells in vitiligo. J Immunol 203(1):11\u201319. https:\/\/doi.org\/10.4049\/jimmunol.1900027","journal-title":"J Immunol Jul"},{"issue":"2","key":"4151_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","volume":"21","author":"S Cheuk","year":"2017","unstructured":"Cheuk S, Schlums H, Gallais Serezal I et al (2017) CD49a expression defines Tissue-Resident CD8(+) T cells poised for cytotoxic function in human skin. Immun 46(2):287\u2013300. https:\/\/doi.org\/10.1016\/j.immuni.2017.01.009","journal-title":"Immun Feb"},{"issue":"1","key":"4151_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/09546634.2020.1735615","volume":"33","author":"K Phan","year":"2022","unstructured":"Phan K, Phan S, Shumack S, Gupta M (2022) Repigmentation in vitiligo using Janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis. J Dermatolog Treat 33(1):173\u2013177. https:\/\/doi.org\/10.1080\/09546634.2020.1735615","journal-title":"J Dermatolog Treat Feb"},{"issue":"2","key":"4151_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","volume":"88","author":"K Ezzedine","year":"2023","unstructured":"Ezzedine K, Peeva E, Yamaguchi Y et al (2023) Efficacy and safety of oral Ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. J Am Acad Dermatol 88(2):395\u2013403. https:\/\/doi.org\/10.1016\/j.jaad.2022.11.005","journal-title":"J Am Acad Dermatol Feb"},{"issue":"6","key":"4151_CR16","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1111\/ijd.16323","volume":"62","author":"DJ Aickara","year":"2023","unstructured":"Aickara DJ, Patel S, Rosen J, Alonso-Llamazares J (2023) Significant improvement of vitiligo with oral Tofacitinib treatment. Int J Dermatol 62(6):e358\u2013e360. https:\/\/doi.org\/10.1111\/ijd.16323","journal-title":"Int J Dermatol Jun"},{"issue":"8","key":"4151_CR17","doi-asserted-by":"publisher","first-page":"102868","DOI":"10.1016\/j.autrev.2021.102868","volume":"20","author":"F Shah","year":"2021","unstructured":"Shah F, Patel S, Begum R, Dwivedi M (2021) Emerging role of tissue resident memory T cells in vitiligo: from pathogenesis to therapeutics. Autoimmun Rev 20(8):102868. https:\/\/doi.org\/10.1016\/j.autrev.2021.102868","journal-title":"Autoimmun Rev Aug"},{"key":"4151_CR18","doi-asserted-by":"publisher","first-page":"1158883","DOI":"10.3389\/fimmu.2023.1158883","volume":"14","author":"M Wu","year":"2023","unstructured":"Wu M, Wang L, Wu H et al (2023) Leptin deficiency in CD8(+) T cells ameliorates non-segmental vitiligo by reducing interferon-gamma and granzyme B. Front Immunol 14:1158883. https:\/\/doi.org\/10.3389\/fimmu.2023.1158883","journal-title":"Front Immunol"},{"issue":"10302","key":"4151_CR19","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","volume":"28","author":"DP McLornan","year":"2021","unstructured":"McLornan DP, Pope JE, Gotlib J, Harrison CN (2021) Current and future status of JAK inhibitors. Lancet 398(10302):803\u2013816. https:\/\/doi.org\/10.1016\/S0140-6736(21)00438-4","journal-title":"Lancet Aug"},{"key":"4151_CR20","doi-asserted-by":"publisher","unstructured":"Goll GL, Kvien TK (2024) Generic Tofacitinib-A More Affordable JAK Inhibitor. Mayo Clin Proc. 99(1):4\u20136. https:\/\/doi.org\/10.1016\/j.mayocp.2023.11.014","DOI":"10.1016\/j.mayocp.2023.11.014"},{"issue":"6","key":"4151_CR21","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.jaad.2023.07.1016","volume":"89","author":"X Su","year":"2023","unstructured":"Su X, Luo R, Ruan S et al (2023) Efficacy and tolerability of oral Upadacitinib monotherapy in patients with recalcitrant vitiligo. J Am Acad Dermatol Dec 89(6):1257\u20131259. https:\/\/doi.org\/10.1016\/j.jaad.2023.07.1016","journal-title":"J Am Acad Dermatol Dec"},{"key":"4151_CR22","doi-asserted-by":"publisher","unstructured":"Zhu Y, Shi Z, Xu Z et al (2024) Oral Tofacitinib, baricitinib and Upadacitinib monotherapy for steroid-resistant vitiligo: A prospective case series. J Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.20109","DOI":"10.1111\/jdv.20109"},{"issue":"10","key":"4151_CR23","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","volume":"151","author":"BG Craiglow","year":"2015","unstructured":"Craiglow BG, King BA (2015) Tofacitinib citrate for the treatment of vitiligo: A Pathogenesis-Directed therapy. JAMA Dermatol 151(10):1110\u20131112. https:\/\/doi.org\/10.1001\/jamadermatol.2015.1520","journal-title":"JAMA Dermatol Oct"},{"issue":"11","key":"4151_CR24","doi-asserted-by":"publisher","first-page":"e15821","DOI":"10.1111\/dth.15821","volume":"35","author":"H Song","year":"2022","unstructured":"Song H, Hu Z, Zhang S, Yang L, Liu Y, Wang T (2022) Effectiveness and safety of Tofacitinib combined with narrowband ultraviolet B phototherapy for patients with refractory vitiligo in real-world clinical practice. Dermatol Ther 35(11):e15821. https:\/\/doi.org\/10.1111\/dth.15821","journal-title":"Dermatol Ther Nov"},{"issue":"4","key":"4151_CR25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","volume":"77","author":"LY Liu","year":"2017","unstructured":"Liu LY, Strassner JP, Refat MA, Harris JE, King BA (2017) Repigmentation in vitiligo using the Janus kinase inhibitor Tofacitinib May require concomitant light exposure. J Am Acad Dermatol 77(4):675\u2013682e1. https:\/\/doi.org\/10.1016\/j.jaad.2017.05.043","journal-title":"J Am Acad Dermatol Oct"},{"issue":"3","key":"4151_CR26","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamadermatol.2017.5778","volume":"1","author":"SR Kim","year":"2018","unstructured":"Kim SR, Heaton H, Liu LY, King BA (2018) Rapid repigmentation of vitiligo using Tofacitinib plus Low-Dose, narrowband UV-B phototherapy. JAMA Dermatol 154(3):370\u2013371. https:\/\/doi.org\/10.1001\/jamadermatol.2017.5778","journal-title":"JAMA Dermatol Mar"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04151-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04151-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04151-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T06:23:29Z","timestamp":1743402209000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04151-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4151"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04151-9","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Hangzhou Third People\u2019s Hospital (2024KA42). Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"645"}}